What are BPC-157 and TB-500?
BPC-157 — "Body Protection Compound-157" — is a synthetic pentadecapeptide (15 amino acids) that corresponds to a fragment of a protein first identified in human gastric juice. It is unusually stable in solution, which is part of why it became popular in research settings.
TB-500 is a synthetic fragment of Thymosin β-4, a naturally occurring protein that regulates actin, the cytoskeletal protein cells use to move. The fragment is marketed as reproducing much of the parent protein's activity. It is worth being precise here: "TB-500" and full-length "thymosin beta-4" are often used interchangeably in vendor literature, but they are related, not identical — a distinction that matters when you look at the evidence.
Critically, neither is an approved medicine. Both are sold as research chemicals labeled "not for human consumption," and both currently sit in the FDA's Category 2 of bulk drug substances — the tier flagged for significant safety questions, which bars compounding pharmacies from preparing them for people.
What does the human evidence actually show?
This is where honesty matters most, because the gap between marketing and evidence is wide. The overwhelming majority of the "healing" and "recovery" claims attached to both peptides come from animal studies and laboratory experiments — not from controlled trials in people.
For BPC-157, a 2025 narrative review concluded the human evidence is "extremely limited": only a handful of small pilot studies exist, and there is no published randomized controlled trial for any indication. For TB-500, the situation is subtler — the human trial data that exists is really for the full-length parent protein (thymosin β-4), tested as a topical gel for chronic wounds. Those trials found it safe but did not meet their efficacy endpoints. The TB-500 fragment itself has no published human RCT.
The practical takeaway: effects seen in rodents do not reliably translate to humans, so any benefit in people remains unproven for both compounds.
How do the proposed mechanisms differ?
In the preclinical literature, the two are described as working through different pathways. BPC-157's narrative centers on angiogenesis — promoting new blood-vessel formation (via VEGF signaling in animal models) — alongside effects on tendon, ligament, gut, and skin tissue. Notably, in isolated cell cultures it showed no direct angiogenic effect; the effect appeared only in the in-vivo healing context.
TB-500's proposed mechanism centers on actin. By sequestering G-actin (monomeric actin), it is thought to support the rapid cytoskeletal remodeling cells need to migrate — which in turn is linked to wound healing and angiogenesis. So one is framed around blood-vessel and tissue repair, the other around cell movement. Both descriptions, again, rest largely on animal and in-vitro work.
Are they legal — and what about drug testing?
Neither BPC-157 nor TB-500 is approved for human use by the FDA or any major regulator, and both are research-use-only. That alone makes them a poor fit for anyone expecting a vetted therapeutic.
For athletes there is a sharper line: TB-500 (thymosin β-4) is explicitly named on the World Anti-Doping Agency Prohibited List under Section S2.3, banned at all times, in and out of competition. A positive test is an anti-doping rule violation. BPC-157 is also broadly barred in tested sport as a non-approved substance. Anyone in a drug-tested context should treat both as disqualifying.
A note on tracking experimental protocols
PeptidePanel does not sell, source, supply, endorse, or prescribe any compound, and nothing here is medical advice. Both compounds discussed on this page are unapproved and of unverified safety and efficacy in humans.
If you are working with a qualified clinician who is monitoring an experimental protocol, the monitoring discipline is what reduces risk: tracking doses, watching the relevant bloodwork, and documenting any adverse effects. PeptidePanel is a neutral tool for that record-keeping — but the decision to use any investigational compound is one to make only with a licensed physician who understands the risks.